Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2003-10-29
2008-11-25
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
C530S350000, C530S387900, C530S388100, C530S389100
Reexamination Certificate
active
07455839
ABSTRACT:
Inhibins and activins are protein hormones that reciprocally modulate a diversity of regulatory pathways. Competitive binding experiments revealed that betaglycan, the type III TGF-β receptor, also functions as an inhibin receptor. Betaglycan augments the binding of inhibin to the ActRII activin receptor. By augmenting inhibin binding to ActRII, betaglycan effectively sequesters ActRII away from activin and thereby reduces activin signaling. In addition, the ActRII-betaglycan complex may generate novel signals distinct from those initiated by activin signaling via ActRII and ALK4. Betaglycan is produced in discrete nuclei of the rat brain and by specific cell types within the adult rat pituitary, testis, and ovary. The presence of betaglycan within inhibin-responsive tissues and cell types, together with the ability of this protoglycan to bind inhibin and to confer inhibin sensitivity, is consistent with a role of betaglycan as an inhibin-specific receptor mediating inhibin responses within various tissues.
REFERENCES:
patent: 4864019 (1989-09-01), Vale et al.
patent: 4973577 (1990-11-01), Vale et al.
patent: 5102868 (1992-04-01), Woodruff et al.
patent: 5428011 (1995-06-01), Sheth et al.
patent: 5786179 (1998-07-01), Kousoulas et al.
patent: 5830671 (1998-11-01), Dennis et al.
patent: 5929213 (1999-07-01), Lee et al.
patent: 6060460 (2000-05-01), Ferguson
patent: 6692744 (2004-02-01), Vale et al.
patent: 2306481 (1997-05-01), None
patent: WO-9510610 (1995-04-01), None
WoodruffTK, Biochem. Pharmacol.,55, 953-963, 1998.
Shoji et al., Biochem.Biophys.Res.Commun., 246, 320-324, 1998.
Ferguson et al., Genes & Dev., 12, 2636-2649, 1998.
Brown et al., Science, Mar. 1999, vol. 283, pp. 2080-2082.
Alberts et al, Molecular Biology if the Cell, 2nd Edition, 1989, p. 552.
Lewis, K. et al, “Betaglycan Binds Inhibin and Can Mediate Functional Anatagonism of Activin Signalling,” Nature vol. 404, 2000, pp. 411-414.
Chong et al, “Immunocytochemical Localization of Latent Transforming Growth Factor-β1 Activation by Stimulated Macrophages,” Journal of Cellular Physiology vol. 178, 1999, pp. 275-283.
DePaolo et al, “Inhibins, Activins, and Follistatins: The Saga Continues,” P.S.E.B.M. vol. 214, 1997, pp. 328-339.
Chong et al, “Structure and Expression of a Membrane Component of the Inhibin Receptor System,” Endocrinology vol. 141, 2000, pp. 2600-2607.
Kaname et al, “Betaglycan has Multiple Binding Sites for transforming Growth Factor-β1,” Biochemical Journal vol. 315, 1996, pp. 815-820.
Draper et al, “Identification of an Inhibin Receptor in Gonadal Tumors from inhibit α-Subunit knockout Mice,” The Journal of Biological Chemistry vol. 273, 1998, pp. 398-403.
Massague, J., “TGF-Beta Signal Transduction,” Annu Rev Biochem vol. 67, 1998, pp. 753-791.
Massague et al, Cellular Receptors for Type Beta Transforming Growth Factor, J. Biol Chem vol. 260, 1985, pp. 2636-2645.
Lopez-Casillas et al, “Structure and Expression of the Membrane Proteoglycan Betaglycan, a Component of teh TGF-beta Receptor System,” Cell vol. 67, 1991, pp. 785-795.
Wang et al, “Expression Cloning and Characterization of the TGF-beta Type III Receptor,” Cell vol. 67, pp. 797-805.
Derynck et al, “TGF-Beta Receptor Signaling,” Biochim Biophys Acta vol. 1333, pp. F105-150.
Lopez-Casillas et al, “Betaglycan can Act as a Dual Modulator of TGF-Beta Access to Signaling Receptors: Mapping of Ligand Binding and GAG Attachment Sites,” J Cell Biol vol. 124, pp. 557-568.
Sun et al, “Expression of Transforming Growth Factor Beta Type III receptor Suppresses Tumorigenicity of Human Breast Cancer MDA-MB-231 Cells,” J. Biol Chem vol. 272, 1997, pp. 25367-25372.
Chen et al, “Expression of Transforming Growth Factor Beta (TGFbeta) type III Receptor Restores Autocrine TGFbeta1 Activity in Human Breast Cancer MCF-7 Cells,” J. Biol Chem vol. 272, 1997, pp. 12862-12867.
Brown et al, “Requirement of Type III TGF-Beta Receptor for Endocardial Cell Transformation in the Heart,” Science vol. 283, pp. 2080-2082.
LeBrun et al, “Activin and Inhibin have Antagonistic Effects on Ligand-Dependant Heteromerization of the Type I and Type II Activin Receptors and Human Erythroid Differentiation,” Molecular and Cellular Biology vol. 17, No. 3, Mar. 1997, pp. 1682-1691.
Bilezikjian Louise M.
Blount Amy L.
Gray Peter C.
Lewis Kathy A.
Vale Wylie
Fulbright & Jaworski LLP
Research Development Foundation
Spector Lorraine
Stoica Elly-Gerald
LandOfFree
Method of inhibiting the formation of inhibin/betaglycan... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting the formation of inhibin/betaglycan..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting the formation of inhibin/betaglycan... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4049039